John Quisel, Disc Medicine CEO
Disc Medicine blames 'outsized' placebo response on mixed Phase 2 data in rare blood disorder
Despite driving reductions in a key biomarker, Disc Medicine’s drug for a rare blood disorder flunked on efficacy in a Phase 2 study. The company …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
